Fast Market Research recommends "Complera (HIV) - Forecast and Market Analysis to 2022" from GlobalData, now available

Boston, MA -- (SBWire) -- 05/27/2013 --Complera (HIV) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, "Complera (HIV) - Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

View Full Report Details and Table of Contents

Complera is a fixed-dose combination of two NRTIs, Emtriva (emtricitabine/FTC) and Viread (tenofovir disoproxil fumarate/TDF), and a single NNRTI, Edurant (rilpivirine/RPV). Complera is indicated for use as a complete regimen for the treatment of HIV infection in treatment-naive adults. Complera's mechanism of action involves the following (Complera Prescribing information, 2012).

FTC, a synthetic nucleoside analog of cytidine, inhibits the activity of HIV reverse transcriptase (RT) by competing with a natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA resulting in the termination of replication.

TDF, an acyclic nucleoside phosphonate diester analog of adenosine monophosphate, is converted into its active form (i.e., tenofovir diphosphate) by normal metabolic processes. Tenofovir diphosphate inhibits the activity of the HIV RT by competing with deoxyadenosine 5'-triphosphate (a natural substrate) and by terminating viral replication if the drug is incorporated into the viral DNA.
RPV noncompetitively inhibits HIV RT by binding to a distinct position away from the active site of the enzyme.

Scope

- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Complera including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Complera for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: HIV - Brazil Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - Italy Drug Forecast and Market Analysis to 2022
- 572-Trii (HIV) - Forecast and Market Analysis to 2022